Concord Biotech (CONCORDBIO) Fundamentals 2026 — P/E 51.6x, Revenue Analysis | SniperIQ
Concord Biotech (CONCORDBIO) is a India-listed Healthcare company in Biotechnology with a market capitalization of ₹13,479 Crore, trading at ₹1287.95 on the BSE. This SniperIQ fundamentals page covers Concord Biotech's valuation (P/E 51.6x, P/B 6.7x), profitability (net margin 24.7%), revenue (₹1,055 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Concord Biotech's market cap?
Concord Biotech (CONCORDBIO) has a market capitalization of approximately ₹13,479 Crore, trading at ₹1287.95 on the BSE. Market cap moves with the live share price.
What is Concord Biotech's P/E ratio?
Concord Biotech's trailing twelve-month P/E ratio is 51.6x, with a price-to-book (P/B) of 6.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Concord Biotech?
Concord Biotech runs a net profit margin of 24.7%, a gross margin of 55.8%, and an operating margin of 32.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Concord Biotech generate?
Concord Biotech reported revenue of ₹1,055 Crore for fiscal year 2026, with net income of ₹261 Crore and earnings per share (EPS) of 24.78. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Concord Biotech pay a dividend?
Concord Biotech offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Concord Biotech financially healthy?
Concord Biotech carries a debt-to-equity ratio of 0.00x and a current ratio of 7.39x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Concord Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Concord Biotech (CONCORDBIO) the key facts are: market cap ₹13,479 Crore, P/E 51.6x, revenue ₹1,055 Crore, 52-week range 987.05-1979.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Concord Biotech's full fundamentals live
Get Concord Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.